🟢 Eli Lilly is trading 3.22% up today after Phase III brenipatide depression study registration

Eli Lilly is trading $1221.23 (+3.22%) after registration of a Phase III brenipatide study in adults with depression.

• Healthcare is also outperforming, with the sector up 1.59% as investors rotate defensively amid broader market weakness.
• The company-specific pipeline development appears to be the primary catalyst, supported by favorable sector momentum.